Longitudinal monitoring of cell-free DNA methylation in ALK-positive non-small cell lung cancer patients
DNA methylation (5-mC) signals in cell-free DNA (cfDNA) of cancer patients represent promising biomarkers for minimally invasive tumor detection. The high abundance of cancer-associated 5-mC alterations permits parallel and highly sensitive assessment of multiple 5-mC biomarkers. Here, we performed...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) |
| Language: | English |
| Published: |
02 December 2022
|
| In: |
Clinical epigenetics
Year: 2022, Volume: 14, Pages: 1-15 |
| ISSN: | 1868-7083 |
| DOI: | 10.1186/s13148-022-01387-4 |
| Online Access: | Verlag, kostenfrei, Volltext: https://doi.org/10.1186/s13148-022-01387-4 Verlag, kostenfrei, Volltext: https://clinicalepigeneticsjournal.biomedcentral.com/articles/10.1186/s13148-022-01387-4 |
| Author Notes: | Florian Janke, Arlou Kristina Angeles, Anja Lisa Riediger, Simone Bauer, Martin Reck, Albrecht Stenzinger, Marc A. Schneider, Thomas Muley, Michael Thomas, Petros Christopoulos and Holger Sültmann |
| Summary: | DNA methylation (5-mC) signals in cell-free DNA (cfDNA) of cancer patients represent promising biomarkers for minimally invasive tumor detection. The high abundance of cancer-associated 5-mC alterations permits parallel and highly sensitive assessment of multiple 5-mC biomarkers. Here, we performed genome-wide 5-mC profiling in the plasma of metastatic ALK-rearranged non-small cell lung cancer (NSCLC) patients receiving tyrosine kinase inhibitor therapy. We established a strategy to identify ALK-specific 5-mC changes from cfDNA and demonstrated the suitability of the identified markers for cancer detection, prognosis, and therapy monitoring. |
|---|---|
| Item Description: | Gesehen am 16.11.2023 |
| Physical Description: | Online Resource |
| ISSN: | 1868-7083 |
| DOI: | 10.1186/s13148-022-01387-4 |